-+ 0.00%
-+ 0.00%
-+ 0.00%

Junshi Biotech (01877): New indications of Tuoyi® are included in the national health insurance catalogue

Zhitongcaijing·11/16/2026 00:33:14
Listen to the news

Zhitong Finance App News, Junshi Biotech (01877) issued an announcement. Recently, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the “Company”) product treprilizumab injection (trade name: Tuoyi®, product code: JS001) combined with viducitumab for locally advanced or metastatic urothelial cancer expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (hereinafter referred to as the “National Health Insurance Catalogue”) category B. The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2027.

As of the disclosure date of this announcement, Tuoyi® has included all 13 indications approved for marketing in mainland China in the national medical insurance catalogue. It is the only anti-PD-1 monoclonal antibody drug used to treat triple-negative breast cancer, melanoma, first-line kidney cancer, and first-line urothelial cancer in the catalogue.

Treprilizumab injection is the first domestically produced monoclonal antibody drug targeting PD-1 approved for marketing in China. It has won the “China Patent Gold Award”, the highest award in the field of national patents. In December 2020, treprilizumab injection passed the national health insurance negotiations for the first time. As of the disclosure date of this announcement, all 13 indications approved in mainland China have been included in the national health insurance catalogue. It is the only anti-PD-1 monoclonal antibody drug used in the treatment of triple-negative breast cancer, melanoma, first-line kidney cancer, and first-line urothelial cancer in the national health insurance catalogue.

In terms of international layout, as of the disclosure date of this announcement, treprilizumab has achieved a global layout on six continents. It has been approved for listing in more than 50 countries and regions around the world, including China, the US, and Europe, and marketing applications from many countries and regions have been submitted/accepted.

The new indications for Tuoyi® have been included in the national health insurance catalogue, reflecting the recognition of the clinical value, patient benefits and degree of innovation of Tuoyi® by the National Health Insurance Administration (hereinafter referred to as the “National Health Insurance Administration”), and highlights the country's attention and support for drug development and industrialization work of innovative local pharmaceutical companies.

The results of this medical insurance negotiation will help the company further improve the affordability and accessibility of Tuoyi® among patients, further promote the marketing of commercial products, increase sales scale, and have a positive impact on the company's long-term business development. The company will actively cooperate to promote the implementation of health insurance policies, continue to promote hospital access, expand core markets and broad market coverage, so as to continuously improve patients' access to medication.